Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 47
- Registration Number
- NCT00777595
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
A Thorough EKG Safety Study of TA-1790 (Avanafil)
- Conditions
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00769041
- Locations
- 🇺🇸
Covance Phase 1 Clinical Unit, Madison, Wisconsin, United States
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
- Conditions
- Interventions
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- Beijing Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT00752947
- Locations
- 🇨🇳
Tieying Sun, Beijing, China
🇨🇳Xiuhong Nie, Beijing, China
Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis
- Conditions
- Interventions
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2011-06-22
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 100
- Registration Number
- NCT00732446
- Locations
- 🇧🇷
Federal University of Sao Paulo, sao Paulo, SP, Brazil
A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.
- Conditions
- Interventions
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT00721344
- Locations
- 🇺🇸
Charles River Clinical Services Northwest, Tacoma, Washington, United States
Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval
- Conditions
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00713336
- Locations
- 🇬🇧
Research Site, Macclesfield, United Kingdom
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00708903
Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 67
- Registration Number
- NCT00699504
- Locations
- 🇺🇸
Charles River Clinical Services NW, Tacoma, Washington, United States
Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Illinois Retina Associates
- Target Recruit Count
- 22
- Registration Number
- NCT00690313
- Locations
- 🇺🇸
Illinois Retina Associates, Harvey, Illinois, United States
Effects of Single Oral Dose Dapagliflozin QT Study
- Conditions
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00688493
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.